Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC lessened its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 16.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 92,475 shares of the biopharmaceutical company's stock after selling 18,155 shares during the period. Los Angeles Capital Management LLC owned approximately 0.07% of Halozyme Therapeutics worth $4,421,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Geode Capital Management LLC grew its holdings in Halozyme Therapeutics by 1.0% during the 3rd quarter. Geode Capital Management LLC now owns 3,060,131 shares of the biopharmaceutical company's stock worth $175,194,000 after acquiring an additional 30,901 shares in the last quarter. Congress Asset Management Co. grew its stake in shares of Halozyme Therapeutics by 446.5% during the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company's stock worth $139,298,000 after purchasing an additional 1,988,238 shares in the last quarter. Boston Trust Walden Corp increased its holdings in Halozyme Therapeutics by 28.0% in the fourth quarter. Boston Trust Walden Corp now owns 874,081 shares of the biopharmaceutical company's stock valued at $41,790,000 after buying an additional 191,465 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in Halozyme Therapeutics by 6.2% during the 3rd quarter. Janus Henderson Group PLC now owns 545,173 shares of the biopharmaceutical company's stock worth $31,204,000 after buying an additional 31,871 shares during the last quarter. Finally, Glenmede Trust Co. NA boosted its position in shares of Halozyme Therapeutics by 28.9% during the 3rd quarter. Glenmede Trust Co. NA now owns 487,131 shares of the biopharmaceutical company's stock worth $27,883,000 after acquiring an additional 109,283 shares in the last quarter. Hedge funds and other institutional investors own 97.79% of the company's stock.

Remove Ads

Insider Activity at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 5,000 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $56.30, for a total value of $281,500.00. Following the completion of the transaction, the director now owns 38,611 shares in the company, valued at $2,173,799.30. This trade represents a 11.46 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Michael J. Labarre sold 1,697 shares of the firm's stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the sale, the senior vice president now owns 173,756 shares of the company's stock, valued at $10,126,499.68. This trade represents a 0.97 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 26,697 shares of company stock worth $1,461,001 over the last 90 days. Company insiders own 2.40% of the company's stock.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ:HALO traded down $1.19 during trading on Monday, reaching $57.96. The company had a trading volume of 1,414,338 shares, compared to its average volume of 1,292,008. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The stock's fifty day moving average price is $54.53 and its 200 day moving average price is $54.72. Halozyme Therapeutics, Inc. has a fifty-two week low of $37.73 and a fifty-two week high of $65.53. The firm has a market capitalization of $7.14 billion, a price-to-earnings ratio of 16.90, a price-to-earnings-growth ratio of 0.42 and a beta of 1.25.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, topping analysts' consensus estimates of $1.17 by $0.02. The company had revenue of $298.01 million during the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. As a group, equities research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Analyst Ratings Changes

HALO has been the topic of several recent analyst reports. Piper Sandler increased their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research note on Friday, January 10th. HC Wainwright boosted their price target on shares of Halozyme Therapeutics from $70.00 to $72.00 and gave the company a "buy" rating in a research report on Wednesday, February 19th. Wells Fargo & Company dropped their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Finally, Benchmark reissued a "buy" rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $62.78.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.